Net Margin: Radiopharm Theranostics Limited (RADX)

Brandmark of Radiopharm Theranostics (RADX)

Aggregate net margins on the GURU.Markets chart correlate with the expansion of licensing agreements with universities, where the parameter value equals -1994.10. Radiopharm Theranostics (RADX) bases its efficiency growth on patent protection for isotopes, which creates barriers for competitors. The stability of these indicators is supported by the implementation of robotic molecule labeling, which minimizes production defects and eliminates employee radiation exposure in laboratories.

radiopharmtheranostics.com (RADX) Net Profit Margin: for the period 12/06/2024 - 11/20/2026

RADX (Radiopharm Theranostics Ltd): analytical breakdowns and indicator data

- company stock exchange capitalization indicators:
Summary company analytics:Radiopharm Theranostics
Flagship merchandise of Radiopharm Theranostics Limited

The metric is calculated as the ratio of net income to total revenue over a specific period. This metric determines the efficiency of converting revenue into the final financial result. For Radiopharm Theranostics (RADX), it reflects the ability to monetize developments in targeted radioisotopes while accounting for high R&D costs. An analysis of historical net margins allows for an assessment of the business's resilience to operating expenses. Positive momentum along this curve indicates an increase in the capitalization of the company's scientific potential.

Main competitors

ONC: Net Sales Margin|Net Margin Halozyme Inc. (HALO)|Net Margin RevMed|Net Return on Sales AAPG (Ascentage Pharma Group)|Net Sales Margin CGON|UroGen Pharma - Net Return on Sales|Bicara Therapeutics - Return on Sales by Net Profit|Net Sales Margin Personalis Inc PSNL|Erasca Oncology - Net Sales Margin|Net Profit Rate DCTH (Delcath Corp)|YMAB: Net Sales Margin|AURA - Company Sales Margin|CADL (Candel Therapeutics Inc.) - Net Sales Margin|Net Return on Sales ARAY (Accuray)|Return on Sales by Net Profit SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Net Margin|Net Margin Citius Oncology, Inc. CTOR|HURA - Return on Sales by Net Profit|protaratx.com - Net Sales Margin|FATE - Net Sales Margin|WHWK: Net Sales Margin|TScan Therapeutics (TCRX) - Net Sales Margin|Net Margin Champions Oncology|Net Margin XBIT|Net Sales Margin CVM|Return on Sales by Net Profit OS Therapies Inc. OSTX|Net Sales Margin ARTV (Artiva Biotherapeutics)|Net Sales Margin Adlai Nortye Ltd. ANL|Veru Inc - Net Sales Margin|Company Sales Margin Tempest Therapeutics TPST|XLO: Net Sales Margin|Enochian BioSciences (RENB) - Net Sales Margin|Return on Sales by Net Profit MURA|Kairos Pharma Ltd - Net Profit Margin|Net Sales Margin OKUR|CytoMed Therapeutics Limited (GDTC) - Net Profitability Margin|Net Sales Margin CRIS (Curis, Inc.)|APLM: Net Return on Sales|Tharimmune Corporation - Net Sales Margin|ADVB: Net Margin|GNPX: Net Sales Margin|CLDI (Calidi Biotherapeutics Inc.) - Net Margin|Net Margin Sunshine Biopharma, Inc.|Net Sales Margin xeneticbio.com|Net Margin Salarius (SLRX)|Return on Sales by Net Profit Purple Biotech PPBT|Net Margin American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Net Margin|Checkpoint Therapeutics Inc. - Net Sales Margin|Net Profit Rate ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Return on Sales by Net Profit|Ikena Oncology, Inc. - Net Profit Rate|Return on Sales by Net Profit NTBL|VIRX: Net Profit Rate|Net Margin MorphoSys Corporation (MOR)|NAYA - Net Margin|Net Sales Margin AAPGV (Ascentage)